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Background. Cancers of the pancreas originate from both the endocrine and exocrine elements of the organ, and represent
a major cause of cancer-related death. This study provides a comprehensive assessment of gene expression for pancreatic
tumors, the normal pancreas, and nonneoplastic pancreatic disease. Methods/Results. DNA microarrays were used to assess
the gene expression for surgically derived pancreatic adenocarcinomas, islet cell tumors, and mesenchymal tumors. The
addition of normal pancreata, isolated islets, isolated pancreatic ducts, and pancreatic adenocarcinoma cell lines enhanced
subsequent analysis by increasing the diversity in gene expression profiles obtained. Exocrine, endocrine, and mesenchymal
tumors displayed unique gene expression profiles. Similarities in gene expression support the pancreatic duct as the origin of
adenocarcinomas. In addition, genes highly expressed in other cancers and associated with specific signal transduction
pathways were also found in pancreatic tumors. Conclusion. The scope of the present work was enhanced by the inclusion of
publicly available datasets that encompass a wide spectrum of human tissues and enabled the identification of candidate
genes that may serve diagnostic and therapeutic goals.
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INTRODUCTION
The aim of this study is to provide a global assessment of gene
expression patterns for the major neoplastic diseases of the
pancreas. We demonstrate that the inclusion of a diverse source of
diseased and normal pancreatic tissues for analysis using DNA
microarrays enhances the identification of gene expression
patterns that can be attributed to specific cell types and pancreatic
diseases.
Pancreatic adenocarcinoma represents a significant health
burden in industrialized countries and represents one of the most
lethal human cancers. It is the fourth-leading cause of cancer-
related death in the United States with a five-year survival rate of
4% [1]. Oligonucleotide microarrays, cDNA microarrays, and
serial analysis of gene expression technologies have been used to
characterize the gene expression profile of pancreatic adenocarci-
nomas [2–5]. These studies have identified candidate genes that
may play a role in disease pathogenesis or may serve as clinical
markers of disease. The analysis of gene expression data for
pancreatic cancer, however, is problematic because of the
pronounced desmoplasia associated with the disease. The actual
neoplastic cells often comprise a minority of the total cell
population within pancreatic tumors, with the majority belonging
to stromal elements. When pancreatic adenocarcinomas have
been compared to normal pancreatic tissues, the robust desmo-
plastic response produced by stromal cells contributes to a gene
expression profile that may dominate over that contributed by the
neoplastic cells themselves. Because other pancreatic diseases are
also known to result in significant desmoplasia, further confound-
ing the interpretation of the patterns seen in cancers, this study
approached the problem by expanding the tissues examined to
include a wide variety of diseased and normal pancreatic tissues.
The present study used samples derived from pancreatic tumors of
exocrine, endocrine, and mesenchymal origin. In addition,
isolated pancreatic islets and ducts from normal tissues as well as
pancreatic cancer cell lines were used to enhance analysis of the
gene expression profile. Each pancreatic tissue and cell line
contributes to an interpretative framework that facilitates identi-
fication of genes whose expression is most characteristic of specific
cell types and diseases. For example, genes that participate in the
desmoplastic response can be distinguished because their expres-
sion is a shared feature in a variety of different pancreatic diseases
in which this response is seen.
Islet cell tumors represent a second major pancreatic tumor
whose pathogenesis is poorly understood and for which effective
therapies are lacking. In contrast to previously published studies
that compared gene expression between islet tumors and normal
islets, the current study also examines gene expression in islet
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diseases [6–8].
The expanding collection of publicly accessible gene expression
data also provides an opportunity to compare and enhance the
dataset provided by this study. For example, the gene expression
profiles of a wide spectrum of normal human tissues [9] provide an
opportunity to compare gene expression profiles of pancreatic
cancer to a detailed overview of the cells and tissues of the human
body, and thereby focus on those features most likely to provide
diagnostic markers for detection of disease.
MATERIALS AND METHODS
Samples and RNA isolation
All participating patients provided consent prior to surgery. The
resected tissue was immediately frozen in liquid nitrogen, and
stored at 280uC. A portion of the sample was processed for
histopathology. Normal pancreatic islets and pancreatic ducts
were obtained from organ donors. Samples were obtained with
approved human subjects protocols from Stanford University,
Samsung Medical Center (Seoul, South Korea), University of
Washington, and the Cooperative Human Tissue Network. Data
derived from 11 adenocarcinoma samples and 5 non-tumor
pancreatic samples included in this report were previously
published in collaboration with Johns Hopkins University [5].
The present study represents the addition of 91 microarray studies
that includes additional adenocarcinomas, islet cell tumors, other
non-adenocarcinomas, benign pancreatic disease, normal isolated
pancreatic islets and ducts, and pancreatic cancer cell lines.
Pancreatic cancer cell lines were obtained from the American
Type Culture Collection (Manassas, VA) and included AsPC-1
(#CRL-1682), BxPC-3 (#CRL-1687), Capan-1 (#HTB-79),
Capan-2 (#HTB-80), CFPAC-1 (#CRL-1918), Hs 766T
(#HTB-134), MIA PaCa-2 (#CRL-1420), PANC-1 (#CRL-
1469), SU.86.86 (#CRL-1837). The cells were grown to 80–
90% confluence in media specified for each cell type. Islets were
isolated from pancreata as previously described [10]. Cells derived
from human pancreatic ducts were initially expanded as a primary
culture and only early passage cells that retained responsiveness to
secretin stimulation were used [11].
Total RNA for all samples was extracted using Trizol
(Invitrogen, Carlsbad, CA) followed by mRNA isolation using
FastTrack
H mRNA (Invitrogen, Carlsbad, CA). RNA amplifica-
tion was performed for the isolated pancreatic duct cells and islets,
3 adenocarcinomas, and the reference mRNA standards using the
procedure described by Wang et al. [12]. Two rounds of
amplifications were used.
Microarray Procedure
DNA microarrays containing 41,125 clones, representing approx-
imately 24,473 unique genes were printed on microscope slides
and processed for hybridization as previously described (http://
cmgm.stanford.edu/pbrown/protocols/index.html) [13,14]. The
sample mRNA was labeled with Cy5-UDP and a common
reference RNA derived from a panel of cell lines was labeled with
Cy3-UDP (Amersham Biosciences, Piscataway, NJ) [14]. The
arrays were scanned using a GenePix 4000A scanner (Axon
Instruments, Molecular Devices Corp., Palo Alto, CA).
Features containing artifacts or blemishes were flagged for
exclusion from further analysis using GenePix Pro 5.0 (Axon
Instruments). The raw data was deposited in the Stanford
Microarray Database (http://genome-www5.stanford.edu) [15].
A total of 9,259 unique genes (represented by 16,959 spots)
satisfied subsequent filtering by exhibiting a mean signal intensity
at least 1.5 fold greater than background for either the Cy5 or Cy3
channels. Only genes for which acceptable data were obtained in
at least 70% of the samples and that showed at least a 1.5-fold
difference in expression from the mean for at least 1 sample were
retained. The expression data were visualized using Treeview [16].
Analysis included a hierarchical clustering algorithm that was
applied to both the genes and arrays, and a supervised analysis by
multi-class comparison using Significance Analysis of Microarrays
(SAM) software [16,17]. Identification of genes capable of
discriminating between classes using shrunken centroids employed
Prediction Analysis of Microarrays (PAM) software [18]. Gene
annotations were obtained using SOURCE (http://source.stan-
ford.edu) [19]. Genes predicted to encode secretory and
membrane proteins were identified using the SignalIP software
program that analyzes amino acid sequences for signal peptides
(HMM/S mean score method)[20] or the TMHMM program that
identifies transmembrane domains[21]. Additional putative secre-
tory and membrane proteins were identified by interrogating an
empirically-derived dataset[22]. Differentially expressed genes in
pancreatic adenocarcinoma that are associated with areas of
chromosome gains or loss were identified using comparative
genomic hybridization data of the 6 cell lines used in the present
study[23]. A high resolution map for regions of DNA copy
number gains and losses was obtained using the CLuster Along
Chromosome (CLAC) method[24].
The entire primary dataset is available at the Stanford
Microarray Database (http://genome-www5.stanford.edu/) or
the Lowe laboratory website (http://www.stanford.edu/group/
lowelab/)
Immunohistochemistry and In-situ hybridization
Immunohistochemistry was performed using Dako Envision Plus
(Glostrup, Denmark) following the manufacturer’s instruction.
Rabbit anti-axin2 serum was from Zymed (Invitrogen, Carlsbad,
CA). Tissue microarrays constructed to evaluate axin2 expression
contained 13 normal pancreata and 26 pancreatic adenocarcino-
mas. Rabbit antibodies against LGALS4 were produced against
peptide sequence NH2-PPYPGPGHCHQQLNS, and for
MUC13 peptide sequence NH2-DPEEKHSMAYQDLHSEC
(AnaSpec, Inc., San Jose, CA).
In situ hybridization was performed as previously described
using paraffin-embedded sections [25].
RESULTS
Gene expression profiles were obtained using cDNA microarrays
for a total of 80 surgically removed pancreatic tissue samples
(Table 1). The majority of the tumors removed were determined
by pathology to be adenocarcinomas. Other pancreatic tissues
collected included islet cell tumors, rare pancreatic tumors,
chronic pancreatitis, and cystic disease. When available, non-
tumor tissue was also collected. Normal pancreatic tissue was
obtained from 9 organ donors.
Additional samples included primary cultures of human
pancreatic duct cells, purified human islets from normal donors,
and nine commercially available pancreatic cancer cell lines. The
human pancreatic duct cells and human islets were harvested from
5 and 9 different donors, respectively, and were processed
separately and not pooled. RNA derived from the pancreatic
duct cells and purified islets required antisense RNA amplification
for the microarray analysis because of lower amounts of starting
material.
We first used an unsupervised hierarchical clustering approach
to organize and explore the data and highlight groups of genes and
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on similarities in their overall gene expression profiles, most
samples were clustered in a manner consistent with their original
pathologic classification, yielding distinct clusters of adenocarci-
nomas, islet cell tumors, and normal pancreatic tissues (Figure 1A).
Thirty-seven of 40 adenocarcinoma samples were grouped in one
of the two major branches of the clustering dendrogram, of which
31 shared very similar expression profiles and were clustered
within the same node. Six adenocarcinomas clustered in an
adjoining node with lymphoma and other mesenchymal tumors,
including 3 adenocarcinomas (shbh111, shbh109, shbt153, see
Data S1 for clinical details) with atypical pathologic features.
These adenocarcinomas were distinguished by higher expression
of genes associated with proliferation and lower expression of the
genes in the ‘‘Adeno’’ clusters 1 and 2. Three adenocarcinomas
that clustered away from the majority of adenocarcinomas
(shcx173, shcx172b, and shcx150) were distinguished by signifi-
cant expression of genes encoding digestive enzymes, such as
pancreatic amylase (AMY2A) and elastase (ELA3A), suggesting
the presence of normal acinar cells in addition to the neoplastic
component. The gene expression profiles for most of the
adenocarcinomas were distinct from non-neoplastic tissues as well
as other pancreatic tumors, including lymphomas, osteoclast
tumors, liposarcomas, and islet-cell tumors. Among the adeno-
carcinomas, no significant segregation was observed on this
analysis that would suggest subclassification into distinct molecular
subtypes that might be associated with differences in tumor or
cellular staging criteria. Clinical outcomes following surgery were
known for 16/39 adenocarcinomas in this dataset (Data S1). The
disease-free interval for almost all patients was less than 2 years.
Among these samples, there was no indication that hierarchical
clustering resulted in any classification by survival length.
Islet cell tumors were derived from four patients. Three samples
from one patient representing separate metastatic lesions are
included. Although immunohistochemistry revealed different
secretory products for 3 patients, the tumors shared sufficient
similarity in gene expression profiles to be clustered together.
Other pancreatic tumors that did not cluster with the adeno-
carcinomas or islet cell tumors included a pancreatic sarcoma,
lymphoma, and osteoclast-like giant cell tumor. Although only
single cases were represented for these rare tumors, they clustered
together with the major common feature consisting of genes
characteristic of the desmoplastic response, and relatively high
expression of genes associated with proliferation.
Non-tumor and normal whole pancreatic tissues consistently
clustered separately from the diseased tissues. The analysis did not
distinguish between uninvolved non-tumor tissue from patients
with cancer and pancreatic tissue from normal donors without any
history of pancreatic disease.
Unsupervised hierarchical clustering also highlighted clusters of
genes specifically associated with adenocarcinomas, islet cell
tumors, and normal pancreata. The diversity of tumors and cell
types in this sample set gave rise to a diversity of gene expression
patterns, many of which appear to represent specific cell types.
Defining the source of the distinctive gene expression patterns was
facilitated by projecting the expression data for clonal pancreatic
cancer cell lines, primary pancreatic duct cultures, and isolated
pancreatic islets alongside the data derived from the previous
clustering analysis (Figure 1B).
Of particular interest in this study was the segregation of genes
associated with adenocarcinomas cells themselves from those
involved in the desmoplastic response. Two gene clusters, labeled
‘‘Adeno 1’’ (297 genes) and ‘‘Adeno 2’’ (88 genes) (Figure 2), were
characterized by higher expression in adenocarcinomas compared
to other tumors or normal pancreatic tissues. The separation into
2 gene clusters is due to the higher relative expression of genes in
adenocarcinomas compared to normal tissues in the ‘‘Adeno 1’’
cluster, as compared to the ‘‘Adeno 2’’ gene cluster. The specificity
of genes within the adenocarcinoma clusters is supported by their
lower expression in lymphoma, sarcoma, osteoclast-like cells, and
islet cell tumors. Contained within each cluster are genes whose
expression was previously associated with pancreatic adenocarci-
noma, including keratin 19 (KRT19), anterior gradient 2 homolog
(AGR2), v-erb-b2 avian erythroblastic leukemia viral oncogene
homolog 3 (ERBB3), mesothelin (MSLN), and prostate stem cell
antigen (PSCA) [5,26–28]. Evidence that hierarchical clustering
successfully distinguished between genes expressed predominantly
in neoplastic epithelial cells and in stromal cells, respectively, is
illustrated by two previously characterized matrix metalloprotei-
nases, MMP14 and MMP2[25]. Expression of MMP14 by
adenocarcinoma cells has been previously established by in situ
hybridization, which is consistent with its clustering within the
‘‘Adeno 1’’ cluster. MMP2 is likewise associated with a separate
cluster consistent with its expression by stromal cells (Figure 2). In
situ hybridization or immunocytochemistry was performed for
selected genes from each ‘‘Adeno’’ cluster and confirmed that the
enhanced gene expression was indeed derived from the neoplastic
cells (Figure 3).
We used significance analysis of microarrays (SAM), a supervised
approach of analysis that incorporates an assessment of statistical
significance, to identify genes that are differentially expressed in
adenocarcinomas compared to the normal pancreas and other
tumors in the dataset [17]. A total of 293 genes with an average
expression at least 3-fold or higher in adenocarcinomas compared
to non-adenocarcinoma samples were identified, with a false
discovery rate of,.00001%. These genes were ranked based on
the statistical significance of their differential expression in
pancreatic adenocarcinoma versus other samples (Data S2).
Among the 293 ranked genes, 176 are associated with the
previously identified ‘‘Adeno 1’’ and ‘‘Adeno 2’’ clusters, and 87
genes are associated with the Stromal cluster. These genes include
many not previously associated with pancreatic adenocarcinoma,
such as galectin-4 (LGALS4), mucin 13 (MUC13), secretory
leukocyte protease inhibitor (SLPI), collagen 17A1 (COL17A1),
and ropporin 1-like (ROPN1L). Available annotations with respect
Table 1. Samples used in the study
......................................................................
Adenocarcinoma* 43
Islet cell tumors (4 patients) 6
Other tumors 4
osteoclast giant cell tumor (1 patient) 2
liposarcoma 1
lymphoma 1
Benign disease 5
chronic pancreatitis 3
pseudocyst 1
mucinous cyst 1
Non-tumor and normals 23
Pancreatic cancer cell lines 9
Primary pancreatic ducts 5
Primary pancreatic islets 9
*3 adenocarciinomas were used solely as amplified samples.
doi:10.1371/journal.pone.0000323.t001
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Stromal
Adeno 2
Normal
Acinar
Islet
Lymphocytes
Proliferation
Adenocarcinomas
Misc. tumors
Non-tumors and Normals
Islet tumors
Non-neoplastic disease
shcx173 AdenoCa
shcx172b AdenoCa
shcx149   Chronic Pancreatitis
shcx150 AdenoCa
shdt047 Normal
shaz032 Non-tumor
shbt1 19 Non-tumor
shbh122 Non-tumor
shaz021 Non-tumor
shcx184 Non-tumor
shcx153 Normal
shcx182 Non-tumor
shcx171 Pseudocyst
shcx162 Non-tumor
shcx170   Chronic Pancreatitis
shcx163 Non-tumor
shcx161 Normal
shcx174 Normal
shcx176 Normal
shcx218 Normal
shdt048 Normal
shdt049 Normal
shdt046 Non-tumor
shdt122 Non-tumor
shdp180 Non-tumor
shdp181 Non-tumor
shdp183 Non-tumor
shcb039 Normal
shcx152 cystic  disease
shbq084 Non-tumor
shbt1 14  Islet tumor - 1a
shbt1 12  Islet tumor - 2
shbt1 13  Islet tumor - 1b
shbt1 15  Islet tumor - 1c
shcx221  Islet tumor - 3
shcb031  Islet tumor - 4
shcx169   Chronic Pancreatitis
shcx151   AdenoCa - periampullary
shbh107 AdenoCa
shbh1 11  AdenoCa - poorly dif f.
shbh109 AdenoCa 
shcx181 AdenoCa
shcb032   Lymphoma
shbt121 Liposarcoma
shbh120 Osteoclast
shcx148 Osteoclast
shbt153 AdenoCa
shcx178   AdenoCa
shbh102  AdenoCa - periampullary
shaz030  AdenoCa - periampullary
shbh108   AdenoCa
shbh121 AdenoCa
shaz028 AdenoCa
shaz019 AdenoCa
shaz018 AdenoCa
shbh1 19 AdenoCa
shaz034 AdenoCa
shbt152 AdenoCa
shcb043 AdenoCa
shcb020 AdenoCa
shcb021 AdenoCa
shcb023 AdenoCa
shcx225 AdenoCa
shcx160 AdenoCa
shcx167 AdenoCa
shdt250 AdenoCa
shdt249 AdenoCa
shdt129 AdenoCa
shdp182 AdenoCa
shdt120 AdenoCa
shcx177 AdenoCa
shcx183 AdenoCa
shcx175 AdenoCa
shcx231 AdenoCa
shdp190 AdenoCa
shdt168 AdenoCa
shcx165 AdenoCa
shcx222 AdenoCa
shcx164   Cystadenoma
shbt131 Cystadenoma
 
shcx224 AsPC-1
shcx227 BxPC-3
shcx216 Capan-1
shcx220 Capan-2
shcx226 CFPAC-1
shcx228 Hs  766T
shcx229 MIA  Paca
shcx219 PANC-1
shcx230 Su.86.86
 
shcx190 Duct
shcx194 Duct
shcx203 Duct
shcx210 Duct
shcx209 Duct
shcx192 Islet
shcx195 Islet
shcx191 Islet
shcx196 Islet
shcx168 Islet
shcx205 Islet
shcx188 Islet
shcx202 Islet
shcx189 Islet
shcx199 Normal
shcx198 Normal
shcx207 Normal
shcx206 AcinarCA
shcx187 AdenoCa
shcx200 AdenoCa
shcx193 AdenoCa
shcx201 AdenoCa
shcx204 AdenoCa
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Adenocarcinoma
Normal
Primary islet
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Figure 1. Unsupervised hierarchical clustering of the patterns of variation in expression for 9,259 genes (represented by 16,959 cDNA) in 80
pancreatic tissue specimens (A). The image uses a color code to represent relative expression levels. Red represents expression levels greater than the
mean for a given gene across all samples. Green represents expression levels less than the mean across samples. A color bar (top) relates color code to
the magnitude of the differences in gene expression relative to the all-sample means for each gene. Grey indicates missing or excluded data. (B)
Image representing gene expression in pancreatic cell lines, primary pancreatic duct and islet cells, normal pancreas, and adenocarcinomas. The cell
lines and amplified samples were each mean-centered separately. The genes presented are organized and displayed in an identical manner to the
genes shown in panel (A). (C) Enlarged view of the array dendrogram shown in panel A along with sample identification.
doi:10.1371/journal.pone.0000323.g001
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PLoS ONE | www.plosone.org 4 March 2007 | Issue 3 | e323to function and subcellular location revealed genes that function in
signal transduction, the cytoskeleton, the extracellular matrix, and
cellular metabolism (Data S2). Recent studies using comparative
genomic hybridization of genomic DNA have produced a high
resolution map for regions of DNA gains and losses for pancreatic
cancer cell lines, including the 6 used in the present study. When
used as a guide, 31 highly expressed genes and 26 genes expressed
at lower levels in adenocarcinomas were also associated with
corresponding areas of frequent DNA copy gains and losses (Data
S3). Supporting the ductal origin of pancreatic adenocarcinomas,
the majority of genes clustered in ‘‘Adeno 1’’ and ‘‘Adeno 2’’ were
similarly highly expressed in isolated pancreatic duct cells. The
same genes also showed higher expression in clonal pancreatic
cancer cell lines. Among the commonly available adenocarcinoma
cell lines, only a subset consisting of AsPC1, BXPC3, Capan-1,
Capan-2, and CFPAC-1, consistently exhibited higher expression
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Figure 2. Expanded view of gene clusters shown in Figure 1A. Color code and experimental conditions are as described for Figure 1.
doi:10.1371/journal.pone.0000323.g002
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mas (Figure 2). In contrast, genes in the stromal cluster exhibited
much lower expression in the pancreatic adenocarcinoma cell lines
and primary pancreatic duct cells. Significance analysis was also
used to identify genes differentially expressed between primary
duct and acinar cells. Because acinar cells comprise ,90% of the
pancreas, differences in gene expression between pancreatic duct
and acinar cells were determined by comparing expression
patterns of normal isolated pancreatic ducts with that of the
normal whole pancreas derived from organ donors. A total of
1,476 genes with at least a 3-fold difference in expression between
the two classes were identified with a false discovery rate of 0.05%.
Again, genes with enhanced expression in the pancreatic ducts
were also similarly expressed in adenocarcinomas (Data S4).
Islet tumors were identified by a cluster of 311 genes with
elevated expression (correlation $0.75). Consistent with their
endocrine origin, these tumors were characterized by elevated
levels of transcripts encoding chromogranins A and B (CHGA,
CHGB), secretogranin II (SCG2), synaptophysin (SYP), peptidyl-
glycine a-amidating monooxygenase (PAM), dopa decarboxylase
(DDC), and somatostatin receptor 1 (SSTR1) (Data S5). Genes in
the islet tumor cluster were generally expressed at high levels in the
isolated islet cells but not in isolated pancreatic duct cells (Figure 2).
Significance analysis identified genes differentially expressed in
islet tumors compared to all other tissue samples in the dataset
(Data S5). Two hundred genes were identified with a false
discovery rate of 3.5%, of which 106 genes showed relatively high
expression in the islet tumors. Consistent with previously published
findings, genes with significantly elevated expression in islet cell
tumors included insulinoma-associated 1 (INSM1), glutaminyl-
peptide cyclotransferase (QPCT), fibrinogen B beta polypeptide
(FGB), peroxisomal biogenesis factor 7 (PEX7). All of these genes
identified by the SAM analysis were within the islet tumor cluster.
Genes not previously described in islet cell tumors, but exhibiting
elevated specific expression, include the AXL receptor tyrosine
kinase (AXL) and the transcription factor V-maf musculoapo-
neurotic fibrosarcoma oncogene homolog B (MAFB). AXL
expression is also elevated in leukemia, melanoma, prostate,
colon, endometrial, and thyroid cancers[29–32]. Increased MAFB
gene expression has been observed in myeloma [33]. INSM1,
AXL, and MAFB are all located on chromosome 20 where
comparative genomic hybridization studies have detected high-
level amplification[34,35].
A group of genes was expressed at higher levels in non-tumor
and normal pancreatic tissues than in either islet cell tumors or
adenocarcinomas. Acinar cells represent 90% of the cellular
composition of the pancreas and are expected to dominate the
expression profile of the normal pancreas. Genes encoding
digestive enzymes produced by acinar cells such as amylase
(AMY2A), elastase (ELA3A, ELA3B), carboxypeptidase A (CPA2),
pancreatic lipase (PNLIP), and trypsin (PRSS2) were enriched in
this cluster (Figures 1, ‘‘Acinar’’ cluster).
Genes known to be associated with the desmoplastic response in
pancreatic cancer were clustered separately from the adenocarci-
noma clusters. These genes included osteonectin (SPARC),
fibronectin (FN1), versican (CSPG2), and collagen type 1A2
(COL1A2), tissue inhibitor of metalloproteinase 1 (TIMP1),
biglycan (BGN), matrix metalloproteinase 2 (MMP2), and
stromelysin-1 (MMP3) [5,36–38]. The desmoplasia associated
gene expression pattern was not seen in islet cell tumors, normal
pancreatic tissues, pancreatic adenocarcinoma cell lines, or
isolated pancreatic ducts, but was seen in other tumors such as
lymphoma, sarcoma, osteoclast-like giant cell tumors, and
adenocarcinomas. The expression of the stromal genes in tumors
Figure 3. Immunohistochemistry of paraffin embedded pancreatic adenocarcinomas. Anti-galectin 4 (LGALS4) antibody (panel a). In situ hybridization
for collagen 17A1 (COL17A1) (panel b) and mucin 13 (MUC13) (panel c). In situ hybridization sense control for MUC13 (panel d).
doi:10.1371/journal.pone.0000323.g003
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Figure 4. Cluster analysis of secretory and membrane proteins. Unsupervised hierarchical cluster analysis of expression of 187 genes encoding putative
membrane or secreted proteins in normal pancreas, pancreatic adenocarcinoma, islet cell tumor tissues and a panel of normal tissues [9]. Only genes
for which 80% of spots met quality criteria were used. The figure shows 187 genes representing secretory or membrane-bound proteins that show
enhanced expression in pancreatic adenocarcinomas or islet cell tumors. An enlarged view of the array dendrogram along with sample identification
is shown on the right. A color bar (top) relates color code to the magnitude of the differences in gene expression relative to the all-sample means for
each gene. Grey indicates missing or excluded data.
doi:10.1371/journal.pone.0000323.g004
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in a gene cluster distinct from the ‘‘Adeno’’ clusters, where
expression was specifically associated with adenocarcinomas.
Additional analysis was performed to identify genes potentially
useful for diagnostic and therapeutic purposes. As secretory or
membrane proteins may be especially useful as diagnostic markers
or therapeutic targets, each gene enriched in pancreatic cancer or
islet cell tumors was further analyzed using algorithms to identify
signal peptide or transmembrane domains. For pancreatic cancer,
only genes within the ‘‘Adeno’’ clusters were analyzed because
they are enriched in adenocarcinoma cells and do not include the
stromal genes common to other pancreatic diseases. Of the 259
genes in the ‘‘Adeno’’ clusters, 126 were classified as secretory or
membrane proteins by amino acid sequence analysis. An
additional 71 genes, for a total of 197, were identified using
a recently defined dataset by Diehn et al. in which a genome-wide
screen for secretory proteins was empirically determined using
similar DNA microarrays [22]. For the 107 genes identified by
significance analysis of microarrays with high expression in islet
cell tumors, 32 were classified using sequence analysis as encoding
secretory or membrane proteins, and an additional 20 genes were
identified using the empirically derived dataset. These putative
membrane/secreted protein encoding genes identified for pancre-
atic cancer and islet cell tumors were then examined using
unsupervised hierarchical clustering in the context of a diverse
collection of normal human tissues. The approach utilized the
recently published gene expression profiles obtained from a diverse
collection of normal human tissues, obtained using technologies
and methods identical to those used in the present study [9]. The
resultant set of putative secretory and membrane protein genes
were able to distinctly cluster the pancreatic adenocarcinomas,
islet cell tumors, and each of the normal tissues (Figure 4). None of
the genes examined were uniquely expressed in pancreatic
adenocarcinomas or islet cell tumors as each was detectably
expressed in one or more normal tissues. Prediction analysis of
microarrays (PAM), an algorithm that employs shrunken centroids
[18] to identify genes capable of discriminating between different
predetermined classes, identified a set of 16 genes whose
expression pattern was capable of distinguishing 31 of 31
adenocarcinomas and a set of 12 genes whose expression pattern
was capable of distinguishing 6 of 6 islet cell tumor samples from
all normal tissues (Table 2 and Data S6). Four out of 121 non-
adenocarcinomas were misclassified with the adenocarcinomas.
None of the 150 non-islet cell tumor tissues were misclassified as
tumors.
Mutational activation of the Wnt pathway is one of the most
common genetic steps in the pathogenesis of gastrointestinal
cancers. Expression of AXIN2, a marker for Wnt pathway
activation [39–41], was generally higher in pancreatic adenocar-
cinomas compared to primary pancreatic duct cells (Figure 5).
AXIN2 expression was also elevated in islet cell tumors, which
likely contributed to its clustering away from the previously
Table 2. Genes that discriminate adenocarcinoma and islet cell tumors from normal human tissues
..................................................................................................................................................
Gene Symbol Name Clone ID
Pancreatic Adenocarcinoma
LAMC2 Transcribed locus, homologous to laminin, gamma 2 IMAGE:460403
CTSE Cathepsin E IMAGE:243202
GPX2 Glutathione peroxidase 2 (gastrointestinal) IMAGE:587847
LGALS4 Lectin, galactoside-binding, soluble, 4 (galectin 4) IMAGE:511068
GPRC5A G protein-coupled receptor, family C, group 5, member A IMAGE:595037
MMP14 Matrix metallopeptidase 14 (membrane-inserted) IMAGE:270505
ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor IMAGE:525246
AGR2 Anterior gradient 2 homolog (Xenopus laevis) IMAGE:2321113
COL17A1 Collagen, type XVII, alpha 1 IMAGE:252259
TSPAN8 Tetraspanin 8 IMAGE:509731
GPRC5A G protein-coupled receptor, family C, group 5, member A IMAGE:1457276
CEACAM7 Carcinoembryonic antigen-related cell adhesion molecule 7 IMAGE:509688
Islet Cell Tumors
SCG2 Secretogranin II (chromogranin C) IMAGE:174627
RASSF7 Ras association (RalGDS/AF-6) domain family 7 IMAGE:1573778
TTR Transthyretin (prealbumin, amyloidosis type I) IMAGE:1868551
SGNE1 Neuroendocrine protein 1 (putative) IMAGE:878836
INSM1 Insulinoma-associated 1 IMAGE:22895
PCSK2 Proprotein convertase subtilisin/kexin type 2 IMAGE:24254
QPCT Glutaminyl-peptide cyclotransferase IMAGE:711918
FGB **Fibrinogen beta chain IMAGE:84713
PEX7 Peroxisomal biogenesis factor 7 IMAGE:2018758
PTPRN2 Protein tyrosine phosphatase, receptor type IMAGE: 812968
SERPINA1 Serpin peptidase inhibitor IMAGE:294578
ARF3 ADP-ribosylation factor 3 IMAGE:291097
doi:10.1371/journal.pone.0000323.t002
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PLoS ONE | www.plosone.org 8 March 2007 | Issue 3 | e323identified adenocarcinoma gene clusters. Immunocytochemistry
using tissue microarrays of pancreatic tissues revealed positive
axin2 staining in 15 of 26 adenocarcinomas. No staining was seen
in 13 normal pancreata.
DISCUSSION
DNA microarray analysis of global gene expression patterns in
a diverse collection of normal and diseased pancreatic tissues
allowed identification of specific gene expression profiles for
pancreatic adenocarcinomas, islet cell tumors, and the normal
pancreas. Interpretation of the gene expression profiles was
facilitated by the parallel analysis of gene expression in primary
pancreatic ducts and islets, and pancreatic cancer cell lines. The
approach identified genes that are specifically expressed by
neoplastic or stromal cells. Supporting the approach is the
identification of many genes previously associated with pancreatic
adenocarciomas or islet cell tumors. Many other genes not
previously associated with these cancers were also newly identified.
The availability of publicly available gene expression data
provided an opportunity to compare the gene expression patterns
of pancreatic adenocarcinomas and islet cell tumors to those of
many other normal tissues. Other available datasets enabled the
association of differentially expressed genes with areas of genomic
DNA gains and losses. Similar gene expression datasets for other
adenocarcinomas including hepatic, gastric, and breast tumors
provide an opportunity for additional comparisons[9,14,42,43]. In
addition, the identification of secretory and membrane proteins
using computational algorithms or annotations derived from
genome-wide empirical assessments of mRNA localization further
enhance of our ability to identify likely candidates for diagnostic
and therapeutic purposes.
The present study also provides a characterization of the gene
expression profile for islet cell tumors in the context of the whole
pancreas. The gene expression profile for neuroendocrine tumors
in patients with the MEN1 syndrome was recently reported [44].
The syndrome is characterized by neuroendocrine tumors of the
parathyroids, pituitary, and pancreatic islets. Of the 6 patients with
islet cell tumors studied, 2 exhibited insulinomas, which were
compared to that of purified human islets from normal subjects.
The differentially expressed genes in the MEN1 syndrome were
Figure 5. Axin 2 expression in islet cell tumors and adenocarcinomas. Pseudocolored image of axin 2 expression (top). Image represents mean centered
values of sample/reference ratios. Representative immunohistochemistry with rabbit anti-axin2 antibodies in normal pancreas (bottom left) and
pancreatic adenocarcinoma (bottom right).
doi:10.1371/journal.pone.0000323.g005
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pathogenesis for spontaneous islet cell tumors. Our analysis
identified additional genes, including AXL, MFAB, and AXIN2,
whose elevated expression in islet cell tumors suggests signal
transduction pathways important in their development.
Among pancreatic tumors, the adenocarcinomas are the most
common and the most deadly. Distinct and characteristic
differences in gene expression patterns have revealed subclasses
of common tumors, such as breast cancer, that also differ with
respect to their natural history or response to therapy[45]. In
contrast, patients afflicted with pancreatic adenocarcinoma
generally follow a similar course. Consistent with the uniformity
of the clinical course, the gene expression profile for the majority
of adenocarcinomas in the present study was quite uniform,
suggesting that the disease is relatively homogenous. Although the
present study is biased toward patients with surgically resectable
tumors, differences in gene expression profiles would have been
expected if significant biological differences among pancreatic
adenocarcinomas were common.
Our results provide evidence that the Wnt pathway may often
be activated in pancreatic adenocarcinoma and islet cell tumors.
Evidence for Wnt pathway activation in pancreatic cancer has
been inconclusive because nuclear staining for b-catenin, a medi-
ator of Wnt signaling, is observed in less than 5% of cases [46].
Wnt pathway activation has been previously inferred from the
altered cellular distribution of b-catenin in pancreatic adenocarci-
nomas, with decreased plasma membrane and increased cytoplas-
mic staining compared to normal pancreatic ducts and acinar cells
by immunohistochemistry [46]. Recent studies have established
that Axin2 expression is induced by Wnt pathway activation and
serves as a useful marker. Higher expression of Axin2 in pancreatic
adenocarcinomas and islet tumors compared to their non-
neoplastic counterparts supports the potential importance of
Wnt pathway activation in these tumors. A systematic search for
mutations in genes involved in the Wnt pathway may yield new
insights into the pathogenesis of these cancers.
The present study provides a comprehensive analysis of gene
expression in pancreatic tumors. The analysis of a broad spectrum
of pancreatic tissues in conjunction with publicly available datasets
and software tools enhanced the identification of genes that may
participate in disease pathogenesis, or may serve as preferred
targets for diagnostic or therapeutic strategies.
SUPPORTING INFORMATION
Data S1 Clinical staging and outcomes for the samples used in
Figure 1.
Found at: doi:10.1371/journal.pone.0000323.s001 (0.03 MB
XLS)
Data S2 List of genes within the Adeno 1 and 2 clusters.
Annotated gene list identified by significance analysis of micro-
arrays versus all other non-adenocarcinoma pancreatic tissues.
Only the 31 adenocarcinomas grouped together in Figure 1 were
used for the analysis. Worksheets also contain analysis for the
identification of putative secretory and membrane proteins and
genes that are associated with DNA copy gains and losses as
determined by CGH. A table of contents is contained in the first
Excel worksheet.
Found at: doi:10.1371/journal.pone.0000323.s002 (1.91 MB
XLS)
Data S3 Table of differentially expressed genes identified by
SAM in adenocarcinomas whose genomic location showed high
DNA copy gains or losses.
Found at: doi:10.1371/journal.pone.0000323.s003 (0.03 MB
XLS)
Data S4 List of genes differentially expressed between primary
pancreatic duct cells and whole normal pancreatic tissue obtained
using SAM as described in the Methods.
Found at: doi:10.1371/journal.pone.0000323.s004 (2.12 MB
XLS)
Data S5 List of genes within the islet cell tumor cluster.
Annotated list of genes identified by SAM that are differentially
expressed in islet tumors compared to all other pancreatic tissues
in the dataset.
Found at: doi:10.1371/journal.pone.0000323.s005 (0.43 MB
XLS)
Data S6 Identification of candidate genes capable of discrimi-
nating pancreatic adenocarcinomas or islet cell tumors from
a diverse collection of normal human tissues. Putative secretory or
membrane proteins enriched in pancreatic adenocarcinomas or
islet cell tumors in the current study were examined in the context
of a wide variety of normal tissues reported in reference [9].
Found at: doi:10.1371/journal.pone.0000323.s006 (0.05 MB
XLS)
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